anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glucagon-like peptide-1 (GLP-1) agonists play a crucial role in treating type 2 diabetes mellitus and obesity by providing glycemic control and aiding weight management. Despite their widespread use, concerns about serious adverse events have prompted extensive research. This review aims to describe the current understanding of serious adverse events associated with GLP-1 agonists. A comprehensive search of PubMed, Google Scholar and Embase databases was performed starting from 2010. Studies reporting evidence of an association between GLP-1 agonists and serious adverse events from 22 articles (5 case reports, 5 randomized controlled trials (RCTs), 9 real-world data cohort analyses, 2 meta-analyses and 1 systematic review and meta-analysis) were included and categorized by the type of adverse event. While some studies reported risks, including anaphylaxis, cardiovascular, gastrointestinal, psychiatric and thyroid-related events, others found no significant associations. The evidence remains mixed, necessitating further research to fully understand the safety profile of GLP-1 agonists and inform clinical practice.
Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
Midodrine hydrochloride forms an active metabolite, desglymidodrine, that is an alpha1-agonist and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors. Desglymidodrine diffuses poorly across the blood-brain barrier and is therefore not associated with effects on the central nervous system.

Administration of midodrine hydrochloride results in a rise in standing, sitting and supine systolic and diastolic blood pressure in patients with orthostatic hypotension of various etiologies. Standing systolic blood pressure is elevated by approximately 15 mmHg to 30 mmHg at 1 hour after a 10 mg dose of midodrine, with some effect persisting for 2 to 3 hours. Midodrine hydrochloride has no clinically significant effect on standing or supine pulse rates in patients with autonomic failure.
The subjective titration procedure in this study will be based on self-reported evolution of symptoms and physical limits of the OSAHS patients. Patients will be recalled to the hospital every 1-2 weeks and will be asked about the subjective changes such as snoring, daytime sleepiness，ache of tooth, temporomandibular pain and so on. Then, the clinicians will adjust the MAD to increase degree of mandibular advancement by 0.5-1mm each time. The patients will adapt this new mandibular advancement for 1-2 weeks and have to come back to hospital for further adjustment until an improvement or a resolution of symptoms occurs, or until the patients could not tolerate any further advancement.
Cefuroxime, USP is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the following structural formula: 

The molecular formula is C16H15N4NaO8S, representing a molecular weight of 446.4.

Cefuroxime for Injection, USP contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. 

Cefuroxime for Injection, USP in sterile crystalline form is supplied in vials equivalent to 750 mg or 1.5 g of cefuroxime as cefuroxime sodium. Solutions of Cefuroxime for Injection, USP range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5.
Patients administered for residential treatment of severe obesity will be included. Patients are treated according to standard of care in a multimodal program, focusing on increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support. Residential treatment is possible for a duration of maximum 1 year.
Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
PROBLEM TO BE SOLVED: To obtain an emulsified composition, excellent in dispersibility of a hydrophobic powder and further good in emulsion stability and feeling of use by blending the hydrophobic powder with a nonionic surfactant having a specific hydrophile-lipophile balance(HLB) value and a water-soluble polymer in a specified proportion. SOLUTION: This oil-in-water type emulsified cosmetic is obtained by using a nonionic surfactant having <=12 HLB (0.01-10wt.%), a hydrophobic powder (0.1-20wt.%) and a water-soluble polymer (0.01-10wt.%) in combination. Furthermore, an alkyl-modified carboxyvinyl polymer (0.01-10wt.%) is preferably contained in the system. A Pluronic (R) type surfactant (0.01-10wt.%) is further blended therein to afford an emulsified composition, improved in emulsifiability and excellent in emulsification stability. For example, sorbitan monooleate or POE glycerol monostearate is cited as the nonionic surfactant having <=12 HLB. Talc, a polyamide powder, etc., are cited as the hydrophobic powder and gum arabic, dextran, methyl cellulose, etc., are cited as the water-soluble polymer.
Biocompatible gold nanoparticles of the present invention are biocompatible and can easily have functions. Therefore, it is highly possible to apply the biocompatible gold nanoparticles to a biotechnology and a biomedical field. According to the present invention, the gold nanoparticles are produced by irradiating six proteins different from each other. Each gold nanoparticle has each isoelectric point and thus has activity sensitive to pH. The gold nanoparticles were shown to have an anticancer effect in a cytotoxic analysis. Different proteins were used as a capping agent. Therefore, the gold nanoparticles inhibit growth of cancer cells at different levels at certain density. The degree of penetration of the gold nanoparticles having positive charge was greater than the degree of the gold nanoparticles having negative charge. The gold nanoparticle produced by using the protein as the capping agent is a promising candidate for an anticancer agent and suggests possibility new type of nanoparticle application.
Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
Macrophages has become a promising target of sepsis treatment because macrophages dysfunction contributes to the progress of sepsis. The targeted therapy of sepsis based on macrophages ferroptosis is drawing more and more attention, but the molecular mechanism involved is poorly understood. In this study, Mus musculus-derived macrophages were used for in-vitro experiments. We found that LPS could induce ferroptosis in macrophages via the detection of apoptosis, GSH, lipid peroxide and GPX4 levels. Meanwhile, miR-129-2-3p was up-regulated in macrophages exposure to LPS. Next, we confirmed that miR-129-2-3p promoted the LPS-induced polarization of M1 phenotype in macrophages via the detection of Arg-1 and iNOS levels; miR-129-2-3p promoted the LPS-induced ferroptosis in macrophages. Further, luciferase assay showed that SMAD3 was identified as a target gene of miR-129-2-3p and its expression was negatively regulated by miR-129-2-3p and LPS. SMAD3 could inhibit the LPS-induced polarization of M1 phenotype and ferroptosis in macrophages by targeting GPX4. Collectively, we demonstrated the target gene and molecular mechanism of miR-129-2-3p mediating LPS-induced polarization and ferroptosis in macrophages by targeting the SMAD3-GPX4 axis, which would provide a novel strategy for sepsis targeted therapy based on macrophages polarization and ferroptosis.
Participants will apply Intermittent Pneumatic Compression (IPC) using a customized version of the Arterial Assist Device to both legs for 2 hours daily for a duration of 3 months. The sham device applies a compression sequence of 30 mmHg to the foot, ankle and calf with inflatable cuffs.
OBJECTIVES: To investigate the efficacy and safety of pulsed radiofrequency of the dorsal root ganglion combined with ozone injection for treating acute herpes zoster (HZ) neuralgia in middle-aged and elderly adults.
METHODS: A total of 164 middle-aged and elderly patients with acute HZ were randomly assigned to 2 groups: the pulsed radiofrequency combined with ozone injection group (group A) and the pulsed radiofrequency group (group B). The therapeutic effects were evaluated using Numeric Rating Scale (NRS) scores and the average doses of gabapentin (mg/d) preoperatively and 1 day, 2 weeks, 4 weeks, 12 weeks, and 24 weeks postoperatively. The incidence of clinically significant postherpetic neuralgia (PHN) and complications in the 2 groups were recorded.
RESULTS: The data showed that the NRS scores and the doses of gabapentin after treatment were significantly lower when compared with the baseline values in both groups. Compared with group B, the NRS scores and the doses of postoperative gabapentin were significantly lower in group A. The incidence of PHN was significantly lower at weeks 4, 12, and 24 in group A than in group B. No adverse reactions occurred in either of the 2 groups post-treatment.
CONCLUSIONS: The results indicated that ozone injection in the dorsal root ganglion combined with pulsed radiofrequency therapy was more effective in treating acute HZ neuralgia in middle-aged and elderly adults. It provides patients with longer-lasting pain relief, decreased incidence of PHN and the doses of medication, and improved quality of life than with Pulsed Radiofrequency treatment.
FIELD: medicine. ^ SUBSTANCE: this invention relates to the pharmaceutical industry, in particular to the solution for perfusion, preservation and/or reperfusion of organs, especially heart, for the purpose of transplantation. The solution contains at least one peptide inhibitor of protein kinase C II (PKC II), representing the SEQ ID No:l, and/or at least one peptide inhibitor of protein kinase C , (PKC ), representing SEQ ID No:2 or Go6983 and/or, at least one peptide activator of protein kinase C (PKC ), representing SEQ ID No:2. Also methods of application the solution are described, including the method of preservation of organ for transplantation, protection of ischemic body from injury, reduction of organ dysfunction after ischemia, preserving release of nitric oxide in ischemic organ, and protection of the body from damage when isolated from circulation. ^ EFFECT: this invention enables to protect more effectively the transplanted organ from reperfusion injury after ischemia. ^ 98 cl, 24 dwg, 3 ex
Single oral dose of MK-8510 administered at dose level 2 (≤2200 mg) following a 10-hour fast. Dose level 2 shall not exceed 2200 mg.
BACKGROUND: Human cytomegalovirus (HCMV) is the most common and serious opportunistic infection after solid organ and hematopoietic stem cell transplantation. In this study, we used whole-genome HCMV data to investigate viral factors associated with the clinical outcome.
METHODS: We sequenced HCMV samples from 16 immunocompromised pediatric patients with persistent viremia. Eight of the 16 patients died of complications due to HCMV infection. We also sequenced samples from 35 infected solid organ adult recipients, of whom 1 died with HCMV infection.
RESULTS: We showed that samples from both groups have fixed variants at resistance sites and mixed infections. Next-generation sequencing also revealed nonfixed variants at resistance sites in most of the patients who died (6/9). A machine learning approach identified 10 genes with nonfixed variants in these patients. These genes formed a viral signature that discriminated patients with HCMV infection who died from those who survived with high accuracy (area under the curve = 0.96). Lymphocyte numbers for a subset of patients showed no recovery posttransplant in the patients who died.
CONCLUSIONS: We hypothesize that the viral signature identified in this study may be a useful biomarker for poor response to antiviral drug treatment and indirectly for poor T-cell function, potentially identifying early those patients requiring nonpharmacological interventions.
BACKGROUND: Age is the greatest risk factor for lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH). Although LUTS/BPH can be managed with pharmacotherapy, treatment failure has been putatively attributed to numerous pathological features of BPH (eg, prostatic fibrosis, inflammation). Mitochondrial dysfunction is a hallmark of aging; however, its impact on the pathological features of BPH remains unknown.
METHODS: Publicly available gene array data were analyzed. Immunohistochemistry examined mitochondrial proteins in the human prostate. The effect of complex I inhibition (rotenone) on a prostatic cell line was examined using quantitative polymerase chain reaction, immunocytochemistry, and Seahorse assays. Oleic acid (OA) was tested as a bypass of complex I inhibition. Aged mice were treated with OA to examine its effects on urinary dysfunction. Voiding was assessed longitudinally, and a critical complex I protein measured.
RESULTS: Mitochondrial function and fibrosis genes were altered in BPH. Essential mitochondrial proteins (ie, voltage-dependent anion channels 1 and 2, PTEN-induced kinase 1, and NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial [NDUFS3]) were significantly (p < .05) decreased in BPH. Complex I inhibition in cultured cells resulted in decreased respiration, altered NDUFS3 expression, increased collagen deposition, and gene expression. OA ameliorated these effects. OA-treated aged mice had significantly (p < .05) improved voiding function and higher prostatic NDUFS3 expression.
CONCLUSIONS: Complex I dysfunction is a potential contributor to fibrosis and lower urinary tract dysfunction in aged mice. OA partially bypasses complex I inhibition and therefore should be further investigated as a mitochondrial modulator for treatment of LUTS/BPH. Hypotheses generated in this investigation offer a heretofore unexplored cellular target of interest for the management of LUTS/BPH.
Skull-base chordoma is a rare, aggressive bone cancer with a high recurrence rate. Despite advances in genomic studies, its molecular characteristics and effective therapies remain unknown. Here, we conduct integrative genomics, transcriptomics, proteomics, and phosphoproteomics analyses of 187 skull-base chordoma tumors. In our study, chromosome instability is identified as a prognostic predictor and potential therapeutic target. Multi-omics data reveals downstream effects of chromosome instability, with RPRD1B as a putative target for radiotherapy-resistant patients. Chromosome 1q gain, associated with chromosome instability and upregulated mitochondrial functions, lead to poorer clinical outcomes. Immune subtyping identify an immune cold subtype linked to chromosome 9p/10q loss and immune evasion. Proteomics-based classification reveals subtypes (P-II and P-III) with high chromosome instability and immune cold features, with P-II tumors showing increased invasiveness. These findings, confirmed in 17 paired samples, provide insights into the biology and treatment of skull-base chordoma.
1. A in lungs, comprising administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist to a patient suffering from airway hypersecretion of mucus. 2. The method of Claim 1, wherein said EGF-R antagonist is a kinase inhibitor selective for EGF-R. 3. The method of claim 1, wherein the antagonist is an antibody. 4. The method of claim 3, wherein the antibody is a monoclonal antibody that specifically binds epidermal growth factor (EGF-R). 5. The method of claim 1, wherein said antagonist inhibits transphosphorylation of EGF-R. 6. The method of claim 5, wherein said antagonist is an anti-oxidant. 7. The method of claim 1, wherein the antagonist is administered by injection. 8. The method of claim 7, wherein the antagonist is administered intravenously with a carrier in the form of normal saline solution. 9. The method of claim 1, wherein the antagonist is administered by inhalation. 10. The method of claim 1, wherein the antagonist is administered by liposome delivery. 11. The method of Claim 1, wherein said liposome is sterically stabilized and administered intravenously. 12. An in vitro method for screening candidate agents, comprising: (i) contacting an in vitro model of goblet cell proliferation with EGF or the functional equivalent thereof; (ii) subsequently contacting the in vitro model with a candidate agent; and (iii) assessing goblet cell proliferation; wherein a decrease in goblet cell proliferation is indicative of the agent's therapeutic potential. 13. The method of claim 12, wherein the in vitro models are lung epithelial cells. 14. An in vivo method of screening candidate agents comprising: (i) creating an animal model of hypersecretory pulmonary disease by including EGF-R; (ii) stimulating the induced EGF-R with a ligand, to produce mucin producing goblet cells; (iii) treating with a candidate agent; and (iv) assessing goblet cell proliferation or mucus secretion; wherein an inhibition of goblet cell proliferation or mucus secretion is indicative of the candidate agent's therapeutic potential. 15. The method of claim 14, wherein the animal used in the in vivo model is selected from the group consisting of mouse, rat, rabbit or guinea pig. 16. The method of claim 17, wherein the in vivo model is an asthmatic model. 17. A pharmaceutical formulation for treatment of airway mucus hypersecretion, comprising a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist in a dose sufficient to reduce airway mucus hypersecretion and a flowing composition suitable for administering by inhalation, wherein said EGF-R antagonist is a tyrosynekinase inhibitor. 18. The pharmaceutical formulation of claim 17 which comprises EGF-R antagonist together with a fluid carrier and a propellant. 19. The pharmaceutical formulation of claim 17 in which EGF-R antagonist contained in aqueous or ethanol solution. 20. The pharmaceutical formulation of claim 17 which comprises EGF-R antagonist is included in dry powder composition.
Two types of eccentric exercises will be used. The calf muscle will be eccentrically loaded both with the knee straight and with the knee bent. Each of the two exercises will include an increasing number of repetitions (1. Week, 2-3 weeks, 4-12 weeks) done in 3 sets (e.g. 3x15, 3x20, 3x30 repetitions). The patients will be informed that muscle soreness during the first 1 to 2 weeks of training was to be expected. Patients will receive a visual exercise protocol.
Participants in the active comparator group will participated in the 3 session Mindfulness and Self-care (MBSC) programme. MBSC is facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supported/supplemented with brief homework activities to help embed mindfulness practice.
The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing electronic health records (EHRs) for each ED. Patients will therefore be offered HCV testing based on the result of the screening arm to which they are assigned, and in the case of the targeted arm, the results of the risk assessment evaluation performed by the intake nurse. All randomization will be completely integrated into electronic medical screening systems and workflow at each site. Integration of randomization into the electronic systems will allow for real-time concealed random allocation. Nurses who perform screening and all other ED staff (e.g. physicians, technicians) will understand the conceptual goals of the project but will be blinded to study hypotheses, and patients will be completely blinded to the purpose of the study.

This study will be performed at multiple sites, including the EDs at Denver Health Medical Center (DHMC) (Denver, Colorado), Johns Hopkins Hospital (JHH) (Baltimore, Maryland), and the University of Mississippi Medical Center (UMMC) (Jackson, Mississippi).